These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 8970933)
1. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. Padma-Nathan H; Hellstrom WJ; Kaiser FE; Labasky RF; Lue TF; Nolten WE; Norwood PC; Peterson CA; Shabsigh R; Tam PY; Place VA; Gesundheit N N Engl J Med; 1997 Jan; 336(1):1-7. PubMed ID: 8970933 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. Linet OI; Ogrinc FG N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians. Pangkahila WI Asian J Androl; 2000 Sep; 2(3):233-6. PubMed ID: 11225984 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. Costabile RA; Spevak M; Fishman IJ; Govier FE; Hellstrom WJ; Shabsigh R; Nemo KJ; Rapport JL; Tam PY; Weldon KL; Gesundheit N J Urol; 1998 Oct; 160(4):1325-8. PubMed ID: 9751346 [TBL] [Abstract][Full Text] [Related]
5. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. Peterson CA; Bennett AH; Hellstrom WJ; Kaiser FE; Morley JE; Nemo KJ; Padma-Nathan H; Place VA; Prendergast JJ; Tam PY; Tanagho EA; Todd LK; Varady JC; Gesundheit N J Urol; 1998 May; 159(5):1523-7; discussion 1527-8. PubMed ID: 9554347 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Williams G; Abbou CC; Amar ET; Desvaux P; Flam TA; Lycklama à Nijeholt GA; Lynch SF; Morgan RJ; Müller SC; Porst H; Pryor JP; Ryan P; Witzsch UK; Hall MM; Place VA; Spivack AP; Gesundheit N Br J Urol; 1998 Jun; 81(6):889-94. PubMed ID: 9666777 [TBL] [Abstract][Full Text] [Related]
7. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. Raina R; Pahlajani G; Agarwal A; Zippe CD BJU Int; 2007 Dec; 100(6):1317-21. PubMed ID: 17850385 [TBL] [Abstract][Full Text] [Related]
8. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)]. Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074 [TBL] [Abstract][Full Text] [Related]
9. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis. Benevides MD; Carson CC J Urol; 2000 Mar; 163(3):785-7. PubMed ID: 10687977 [TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Hellstrom WJ; Bennett AH; Gesundheit N; Kaiser FE; Lue TF; Padma-Nathan H; Peterson CA; Tam PY; Todd LK; Varady JC; Place VA Urology; 1996 Dec; 48(6):851-6. PubMed ID: 8973666 [TBL] [Abstract][Full Text] [Related]
11. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. Goldstein I; Lue TF; Padma-Nathan H; Rosen RC; Steers WD; Wicker PA N Engl J Med; 1998 May; 338(20):1397-404. PubMed ID: 9580646 [TBL] [Abstract][Full Text] [Related]
12. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy. Engel JD; McVary KT Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Raina R; Agarwal A; Zaramo CE; Ausmundson S; Mansour D; Zippe CD Int J Impot Res; 2005; 17(1):86-90. PubMed ID: 15526008 [TBL] [Abstract][Full Text] [Related]
14. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction. Bratus D; Hlebic G; Hajdinjak T Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142 [TBL] [Abstract][Full Text] [Related]
15. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184 [TBL] [Abstract][Full Text] [Related]
17. Optimizing the therapeutic approach of transurethral alprostadil. Ekman P; Sjögren L; Englund G; Persson BE BJU Int; 2000 Jul; 86(1):68-74. PubMed ID: 10886086 [TBL] [Abstract][Full Text] [Related]
18. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Nehra A; Blute ML; Barrett DM; Moreland RB Int J Impot Res; 2002 Feb; 14 Suppl 1():S38-42. PubMed ID: 11850734 [TBL] [Abstract][Full Text] [Related]
19. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. Williams G; Abbou CC; Amar ET; Desvaux P; Flam TA; Lycklama à Nijeholt GA; Lynch SF; Morgan RJ; Müller SC; Porst H; Pryor JP; Ryan P; Witzsch UK; Hall MM; Place VA; Spivack AP; Todd LK; Gesundheit N Br J Urol; 1998 Dec; 82(6):847-54. PubMed ID: 9883223 [TBL] [Abstract][Full Text] [Related]
20. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. Safarinejad MR J Diabetes Complications; 2004; 18(4):205-10. PubMed ID: 15207837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]